Thrive Precision Health, Inc. (OTC:CNER) Taking Steps To Serve Diabetic Health Sector

–News Direct–

In the world of healthcare investments, the diabetes care market emerges as a compelling arena ripe with opportunities. Several important factors that may attract some investors are driving the sector's growth.

At the heart of this surge is the continual development of efficient insulin delivery devices. Technological advancements in healthcare are steering manufacturers to innovate in this crucial area. Projections indicate a substantial uptick in the global diabetes care devices market, from $28,942.1 million in 2022 to an anticipated $42,119.3 million by 2028, reflecting a noteworthy compound annual growth rate (CAGR) of 6.4%.

The World Health Organization's recognition of diabetes as a significant global health challenge underscores the urgency for solutions. With over 420 million people affected worldwide, the market demands innovative approaches to address this widespread concern.

The insulin market, valued at $21.11 billion in 2022, signifies a substantial financial domain within the broader diabetes care landscape. Predictions hint at its growth to $25 billion by 2030, with North America playing a prominent role, commanding a considerable 38.91% market revenue share in 2022.

On a domestic scale, the United States presents a vivid picture of the diabetes epidemic. A staggering 37.3 million Americans are diagnosed with diabetes, while an additional 96 million grapple with pre-diabetes. This prevalence is particularly pronounced in the aging population, where 48.8% of those aged 65 or older face the challenges of this health condition.

Looking forward, Global Market Insights anticipates a robust compound annual growth rate of 10% for the diabetes care device market. This projection positions the market to evolve into an $88 billion industry by 2030, offering investors a compelling narrative for potential opportunities in this evolving healthcare landscape.

Among the growing landscape of the diabetes care market, one potential hidden gem poised for prominence is Thrive Precision Health, Inc. (OTC: CNER).

Thrive Precision Health Inc. is carving its niche as a global diabetes care powerhouse. Trading under the symbol CNER, the company is revitalizing established healthcare clinics specializing in diabetes care. Their unique approach integrates cutting-edge technologies, aiming to create a seamless digital experience for patients worldwide, offering personalized healthcare through the application of AI and quantum biosensors.

The company marked a significant milestone on October 5, 2023, by completing a name change to Thrive Precision Health, Inc. This strategic move accompanied the establishment of two wholly-owned subsidiaries, Thrive Testing and Biosafety Inc. and Thrive Precision Health (USA), Inc., signaling a commitment to precision health and a broader global vision.

Thrive Precision Health's expansion strategy takes center stage with a recent press release announcing a binding letter of intent to acquire two diabetes clinics in Arizona. The pending acquisition of True Diabetes Neuropathy and Wounds Solutions AZ, LLC, marks the initiation of their strategy to infuse advanced technology into diabetes care.

The company is diligently developing a standardized clinical footprint designed for scalability across the nation and internationally. Each clinic is expected to offer a range of services, including wound care, IV therapies, neuropathy treatment, and complementary protocols. With up to 20 IV stations and five wound care treatment rooms per clinic, Thrive envisions generating $56 million in total revenues per location, aiming for an impressive 35% EBITDA within each clinic.

Guy Zajonc, CEO and Chairman of Thrive Precision Health, is a prime example of the company's leadership, which places a strong emphasis on precision health and personalized medicine. The CEO of True Diabetes, Dr. Jason Mulder, draws attention to the urgent need in Arizona alone, where millions of people suffer from diabetes and there is a severe shortage of treatment resources.

In the context of a burgeoning diabetes care market, Thrive Precision Health, Inc. (OTC: CNER) emerges as a compelling player with a vision to transform healthcare delivery. Their strategic acquisitions, commitment to precision health, and innovative approach position them as an intriguing opportunity within a sector poised for significant growth. As the demand for personalized diabetes care rises, CNER stands out as a potential cornerstone in this evolving narrative.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, or assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. Capital Gains Report (CGR) is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR has been retained by ACN LLC to produce and distribute this content related to CGER. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content.

Contact Details

Capital Gains Report

Mark McKelvie

+1 585-301-7700

Company Website

View source version on

China New Energy Group Co

comtex tracking


Back to top